Results 21 to 30 of about 65,545 (257)
Background: Since the approval of warfarin, a Vitamin K antagonist anticoagulant (VKA), no other oral anticoagulant existed for patients who needed long-term anticoagulation therapy until the recent introduction of non-VKA oral anticoagulants (NOACs ...
Raphael Chinedu Anakwue
doaj +1 more source
Background For more than a decade, guidelines have recommended a limited 3 months of anticoagulation for the treatment of provoked venous thromboembolism (VTE).
Elizabeth Joyce +10 more
doaj +1 more source
The new oral anticoagulants [PDF]
Anticoagulants have been used for over 70 years for prevention and treatment of potentially fatal thromboembolic events. Heparins and vitamin K antagonists have been the mainstay of treatment and, although effective if managed properly, also have significant drawbacks. Unfractionated heparins (UFH)
Breen, K. A., Hunt, B. J.
openaire +3 more sources
The new oral anticoagulants [PDF]
Abstract Although their first application in clinical practice occurred in the 1940s, vitamin K antagonists remain the only form of oral anticoagulant medication approved for long-term use. Although the available vitamin K antagonists are highly effective for the prevention and/or treatment of most thrombotic disease, the significant ...
David, Garcia +2 more
openaire +5 more sources
Travel and Oral Anticoagulation [PDF]
Millions of individuals worldwide are on permanent or temporary oral anticoagulation treatment with vitamin K antagonists (VKAs). The effectiveness of VKAs has been established by clinical trials for several indications. Among these, the primary or secondary prevention of venous thromboembolism, the prevention of systemic embolism in patients with ...
Jürgen, Ringwald +2 more
openaire +2 more sources
Development and Validation of an Oral Anticoagulation Knowledge Tool (AKT). [PDF]
Assessing and improving patients' anticoagulation knowledge can lead to better treatment outcomes. While validated knowledge instruments exist for use in people taking warfarin, these tools are not necessarily applicable to patients taking direct-acting ...
Kehinde O Obamiro +2 more
doaj +1 more source
BackgroundAn increasing number of patients have received prophylactic or therapeutic oral anticoagulants (OACs) for thromboembolic complications of diseases. The use of OACs is associated with both clinical benefits and risks.
Dai, Hengfen +8 more
doaj +1 more source
Long-term oral anticoagulation for atrial fibrillation in low and middle income countries
With increasing life-expectancy and changing demographics, non-valvular atrial fibrillation (AF) is currently the most common indication for long-term oral anticoagulation (OAC) in low and middle income countries (LMICs). Due to a decreasing trend in the
Venkatakrishnan Ramakumar +2 more
doaj +1 more source
Oral Anticoagulation Thresholds [PDF]
Background Monitoring patients on oral anticoagulation is essential to prevent hemorrhage and recurrent thrombosis. We studied tissue factor–induced whole-blood coagulation in patients on warfarin therapy with similar international ...
K E, Brummel +3 more
openaire +2 more sources
Oral anticoagulation in high risk Takotsubo syndrome: when should it be considered and when not?
Standard pharmacological therapy in Takotsubo syndrome (TTS) is still debated and there is a lack of prospective data. In their recent work in BMC Cardiovascular Disorders Abanador-Kamper et al. found that stroke in TTS has an event rate of 2.8% after 30
Francesco Santoro +5 more
doaj +1 more source

